Perseus Proteomics, Inc. (JP:4882)
:4882
Want to see JP:4882 full AI Analyst Report?
Top Page
Perseus Proteomics, Inc.
(4882)
Select Model
Select Model
Rating:43Neutral
Price Target:
¥141.00
▼(-35.91% Downside)
Action:Reiterated
Date:05/16/26
The score is held down primarily by persistent large losses and ongoing cash burn despite strong revenue growth, alongside a weakening equity base. Technicals are also unfavorable with a clear downtrend, while valuation is constrained by negative earnings and no indicated dividend support.
Positive Factors
Revenue Growth
Consistent multi-year revenue growth demonstrates increasing commercial traction and market acceptance of the company's products. This expanding top line provides a foundation for eventual operating leverage and makes future margin recovery more attainable if fixed costs are absorbed over larger sales volumes.
Negative Factors
Persistent Operating & Net Losses
Chronic operating and net losses indicate that core operations have not reached break-even and suggest structural profitability issues. Continued negative earnings erode retained capital, limit reinvestment capacity, and increase reliance on external financing to sustain R&D and commercialization activities.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent multi-year revenue growth demonstrates increasing commercial traction and market acceptance of the company's products. This expanding top line provides a foundation for eventual operating leverage and makes future margin recovery more attainable if fixed costs are absorbed over larger sales volumes.
Read all positive factors
Perseus Proteomics, Inc. (4882) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥2.48B
Dividend YieldN/A
Average Volume (3M)226.58K
Price to Earnings (P/E)―
Beta (1Y)1.89
Revenue Growth12.57%
EPS Growth22.66%
CountryJP
Employees25
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)-58.44
Shares Outstanding16,999,600
10 Day Avg. Volume184,610
30 Day Avg. Volume226,583
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)2.69
Price to Sales (P/S)24.20
P/FCF Ratio-4.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-62.5
Revenue Forecast (FY)¥120.00M
Perseus Proteomics, Inc. Business Overview & Revenue Model
Company Description
Based in Tokyo, Japan, Perseus Proteomics Inc. operates as a biotechnology venture specializing in the development of antibody-based therapeutics for various ailments, including cancer. Its core operations encompass pioneering antibody discovery, ...
How the Company Makes Money
null...
Perseus Proteomics, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 122.98M | 135.51M | 120.38M | 100.40M | 94.20M | 71.93M |
| Gross Profit | 105.51M | 116.16M | 104.05M | 87.69M | 86.53M | 67.75M |
| EBITDA | -856.49M | -715.80M | -899.49M | -1.10B | -779.36M | -594.14M |
| Net Income | -861.71M | -718.11M | -904.80M | -1.10B | -787.00M | -599.02M |
Balance Sheet | ||||||
| Total Assets | 1.65B | 1.62B | 1.82B | 1.69B | 2.57B | 3.30B |
| Cash, Cash Equivalents and Short-Term Investments | 1.51B | 1.52B | 1.67B | 1.54B | 2.44B | 3.21B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 398.55M | 405.77M | 386.43M | 295.46M | 170.10M | 148.38M |
| Stockholders Equity | 1.26B | 1.22B | 1.43B | 1.40B | 2.40B | 3.15B |
Cash Flow | ||||||
| Free Cash Flow | -181.73M | -662.83M | -794.64M | -976.90M | -734.82M | -510.71M |
| Operating Cash Flow | -155.77M | -653.33M | -719.49M | -833.90M | -564.27M | -476.84M |
| Investing Cash Flow | -25.96M | -10.06M | -75.16M | -150.34M | -212.99M | -33.87M |
| Financing Cash Flow | 459.05M | 497.33M | 923.38M | 63.94M | -20.00K | 2.65B |
Perseus Proteomics, Inc. Technical Analysis
Negative
220.00
Price Trends
196.62
Negative
218.72
Negative
260.48
Negative
Market Momentum
-14.46
Negative
26.45
Positive
35.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4882, the sentiment is Negative. The current price of 220 is above the 20-day moving average (MA) of 158.30, above the 50-day MA of 196.62, and below the 200-day MA of 260.48, indicating a bearish trend. The MACD of -14.46 indicates Negative momentum. The RSI at 26.45 is Positive, neither overbought nor oversold. The STOCH value of 35.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4882.
Perseus Proteomics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ¥7.12B | 20.17 | ― | 4.57% | 8.02% | 43.89% | |
67 Neutral | ¥3.61B | 28.83 | ― | 2.35% | -13.41% | -60.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | ¥5.31B | 39.14 | ― | ― | 11.29% | ― | |
43 Neutral | ¥2.48B | -3.14 | ― | ― | 12.57% | 22.66% | |
43 Neutral | ¥3.58B | -45.69 | ― | ― | 1.30% | 92.91% | |
42 Neutral | ¥12.08B | -20.34 | ― | ― | -25.02% | -697.06% |
* Healthcare Sector Average
JP:4882
Perseus Proteomics, Inc.
146.00
-267.00
-64.65%
JP:2342
Trans Genic Inc.
212.00
49.00
30.06%
JP:3386
Cosmo Bio Co., Ltd.
1,230.00
119.06
10.72%
JP:4978
ReproCELL Inc.
127.00
-65.00
-33.85%
JP:6090
Human Metabolome Technologies, Inc.
610.00
-183.16
-23.09%
JP:7707
Precision System Science Co.,Ltd
192.00
-13.00
-6.34%
Perseus Proteomics, Inc. Corporate Events
Perseus Proteomics Overhauls Board, Taps New Director to Lead Business Development
May 20, 2026
Perseus Proteomics has announced a planned reshuffle of its leadership, appointing Susumu Tanahashi as director, executive officer, and head of both the Business Development and Administrative departments, subject to shareholder approval in June. ...
Perseus Proteomics Books Subsidy Income but Suffers Asset Impairment in FY2026
May 14, 2026
Perseus Proteomics Inc. reported several non-operating items and extraordinary losses in its results for the fiscal year ended March 31, 2026. The biotechnology company, listed on the TSE Growth market, continues to advance proteomics-based RD whi...
Perseus Proteomics Narrows Losses but Withholds FY2027 Forecast Amid Funding Dependence
May 14, 2026
Perseus Proteomics reported net sales of ¥135 million for the year ended March 31, 2026, up 12.6% year on year, but continued to post an operating loss of ¥744 million and a net loss of ¥718 million, albeit narrower than the previou...
Perseus Proteomics Wins AMED Grant to Advance PPMX-T003 for Rare Leukemia
Apr 1, 2026
Perseus Proteomics has secured a JPY 100 million grant under Japan’s FY2026 Drug Discovery Support Promotion Program managed by AMED to advance its antibody candidate PPMX-T003 for aggressive NK-cell leukemia. The funding will support an inv...
Perseus Proteomics Sets FY2026 Forecast, Stays in Red as Licensing Push Continues
Mar 31, 2026
Perseus Proteomics Inc. has issued its previously undetermined full-year earnings forecast for the fiscal year ending March 31, 2026, projecting net sales of 135 million yen and a net loss of 758 million yen, or 50.88 yen per share. The guidance i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.